DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 153 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q2 2024. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $142,843 | – | 10,366 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners XI LLC | 2,491,561 | $30,571,453 | 26.81% |
| Atlas Venture Life Science Advisors, LLC | 7,608,394 | $93,354,994 | 14.46% |
| DAFNA Capital Management LLC | 586,463 | $7,195,901 | 2.24% |
| Nicholas Investment Partners, LP | 2,188,654 | $26,854,785 | 2.01% |
| RA Capital Management | 7,809,852 | $95,826,884 | 1.89% |
| BRAIDWELL LP | 3,715,573 | $45,590,081 | 1.44% |
| PFM Health Sciences, LP | 2,224,598 | $27,295,817 | 1.29% |
| SPHERA FUNDS MANAGEMENT LTD. | 530,000 | $6,503,100 | 1.18% |
| COMMODORE CAPITAL LP | 739,661 | $9,075,640 | 1.06% |
| Parkman Healthcare Partners LLC | 466,408 | $5,722,826 | 1.05% |